Role of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy

医学 新辅助治疗 辅助治疗 食管切除术 食管癌 内科学 佐剂 癌症 肿瘤科 乳腺癌
作者
Yung Lee,Yasith Samarasinghe,Michael H. Lee,Luxmy Thiru,Yaron Shargall,Christian Finley,Waël C. Hanna,Oren Levine,Rosalyn A. Juergens,John Agzarian
出处
期刊:Annals of Surgery [Lippincott Williams & Wilkins]
卷期号:275 (1): 91-98 被引量:35
标识
DOI:10.1097/sla.0000000000005227
摘要

Objective: The aim of this study was to analyze esophageal cancer patients who previously underwent neoadjuvant therapy followed by a curative resection to determine whether additional adjuvant therapy is associated with improved survival outcomes. Summary Background Data: Neoadjuvant therapy followed by surgery is the standard of care for locally advanced esophageal cancer, whereas adjuvant therapy is typically employed for patients with residual disease. However, the role of adjuvant therapy after a curative resection is still uncertain. Methods: MEDLINE, EMBASE, and CENTRAL databases were searched for studies comparing patients with esophageal cancer who underwent neoadjuvant therapy and curative resection with and without adjuvant therapy. Primary outcome was overall survival (OS), and random effects meta-analysis was conducted where appropriate. Grading of recommendations, assessment, development, and evaluation was used to assess the certainty of evidence. Results: Ten studies involving 6462 patients were included. When compared to patients who received neoadjuvant therapy and esophagectomy alone, adjuvant therapy groups experienced a significant decrease in mortality by 48% at 1 year (Risk Ratio (RR) 0.52, 95% confidence interval [CI] 0.41–0.65, P < 0.001, moderate certainty ). This reduction in mortality was carried through to 5-year follow-up (RR 0.91, 95% CI 0.86–0.96, P < 0.001, moderate certainty ). The difference between the adjuvant therapy and the control group was uncertain regarding the secondary outcomes. Conclusion: Adjuvant therapy after neoadjuvant treatment and esophagectomy with negative resection margins provide an improved OS at 1 and 5 years with moderate to high certainty of evidence, but the benefit for disease-free survival and locoregional/distal recurrence remain uncertain due to limited reporting of these outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hello的应助被Liareve采纳,获得10
刚刚
刚刚
尘归尘完成签到,获得积分10
刚刚
Ashore发布了新的文献求助10
1秒前
所所的应助被闪闪的绿旋采纳,获得10
1秒前
Jasper的应助被wydkyd采纳,获得30
1秒前
DF完成签到,获得积分10
2秒前
2秒前
小马甲的应助被瓦伦泰采纳,获得10
2秒前
zmy完成签到 ,获得积分10
3秒前
11111发布了新的文献求助10
4秒前
新晋学术小生完成签到 ,获得积分10
4秒前
4秒前
334niubi666完成签到 ,获得积分10
5秒前
yuanjingnan完成签到,获得积分10
5秒前
QAQ发布了新的文献求助10
6秒前
花花完成签到,获得积分10
6秒前
Dan发布了新的文献求助10
6秒前
chunfengfusu发布了新的文献求助10
6秒前
程伊森发布了新的文献求助10
7秒前
aaa完成签到,获得积分10
7秒前
7秒前
xz完成签到 ,获得积分10
9秒前
9秒前
1618发布了新的文献求助10
9秒前
10秒前
搜集达人的应助被xtc采纳,获得10
11秒前
zorro3574完成签到,获得积分10
14秒前
14秒前
踏实的盼柳的应助被WaNgBO采纳,获得10
14秒前
14秒前
15秒前
BANANA发布了新的文献求助10
15秒前
王乐安完成签到,获得积分10
15秒前
Able完成签到 ,获得积分10
16秒前
时尚篮球完成签到,获得积分10
16秒前
16秒前
赘婿的应助被we采纳,获得10
18秒前
行者发布了新的文献求助10
18秒前
kkm发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158017
求助须知:如何正确求助?哪些是违规求助? 9553900
关于积分的说明 21716555
捐赠科研通 7747340
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551639
邀请新用户注册赠送积分活动 2471005